Document Classification

Section Type: METHODS

Text: Four hundred and twenty-six women with histologically proven 3 cm invasive early breast cancer were randomised to receive pre-operative infusional 5-FU 200 mg/m (2) by daily 24 h continuous infusion via a Hickman line for 18 weeks with epirubicin 60 mg/m (2) intravenous (i. v.) bolus on day 1 and cisplatin 60 mg/m (2) i. v. bolus on day 1, both repeating 3-weekly (infusional ECisF), or conventional bolus doxorubicin 60 mg/m (2) i. v. on day 1 and cyclophosphamide 600 mg/m (2) i. v. on day 1, both repeating 3-weekly (AC), both schedules for six courses.